AstraZeneca narrows review to four

Published on .

AstraZeneca has winnowed contenders to four in a $40 million media buying and planning review for Nexium, the successor to blockbuster heartburn drug Prilosec, an executive close to the situation said. The request for proposals on the account created a tempest among some media executives who felt it asked for too much proprietary information.

Copyright March 2000, Crain Communications Inc.

In this article:
Most Popular